Gan & Lee(SH:603087) Xin Lang Cai Jing·2026-01-04 06:24Core Viewpoint - Gann Li Pharmaceutical (603087.SH) announced the dismissal of its CFO, Sun Cheng, due to business adjustments aimed at globalizing its innovative drug research, marketing, and investment strategies [2][13]. Group 1: Management Changes - The board of directors approved the termination of Sun Cheng's roles as CFO and Vice General Manager, effective immediately, with no further positions held in the company [2][13]. - Sun Cheng held 182,200 shares of restricted stock, valued at approximately 12.4 million yuan based on the closing price of 68.07 yuan per share as of December 31, 2025 [2][13]. - The company will repurchase and cancel 328,000 shares of restricted stock that were granted but not yet released from restrictions [2][13]. Group 2: Background of Sun Cheng - Sun Cheng, born in 1979, is a registered CPA in Australia and holds a master's degree from Tsinghua University. He has held various financial roles, including positions at KPMG and Asia Energy Holdings [3][13]. - His total pre-tax compensation for the year 2024 was reported at 694,900 yuan [5][15]. Group 3: New Acting CFO - Zhou Li, born in 1983 and a master's graduate from Central University of Finance and Economics, has been appointed as the acting CFO. She has been with Gann Li Pharmaceutical since 2012 and served as the finance department director since October 2019 [7][17].